ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the society’s highest honors at the 2025 ASCO Annual Meeting.
Walter M. Stadler was appointed as the chief clinical officer at City of Hope Cancer Center Chicago.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have been awarded a $1.72 million grant from NIH to support the Neuro-Oncology Translational Research Training Program, an initiative designed to train the next generation of brain tumor scientists and physician-scientists.
Tampa General Hospital has been awarded Quality Oncology Practice Initiative Certification based on the approval of the ASCO. This voluntary certification specifically recognizes the TGH Cancer Institute for meeting the strict standards required by the society’s QOPI program.
The Community Oncology Alliance released the COA Prescription for Health Care Reform, a blueprint that diagnoses the fundamental challenges facing the U.S. healthcare system, outlines the consequences for patients across America, and presents “actionable solutions .”
The Wistar Institute’s Hubert J.P. Schoemaker Education and Training Center is expanding its apprenticeship programs and bolstering job opportunities in the life science sector based on a recent $600,000 PASmart Grant from the Pennsylvania Department of Labor & Industry.
Kathryn SchmitzJosé ZevallosUPMC Hillman Cancer Center and the University of Pittsburgh announced that Kathryn Schmitz was appointed interim director of UPMC Hillman. José P. Zevallos was appointed as interim deputy director of UPMC Hillman.
Weiran FengHanzhi LuoQing ChenWeiran Feng, Hanzhi Luo and Qing Chen will join Fox Chase Cancer Center as assistant professors.
Montefiore Einstein Comprehensive Cancer Center earned a three-year accreditation again from the Commission on Cancer of the ACS. MECCC earned “Comprehensive” status from NCI in 2023.
Janet WoodcockPaul T. KimJanet Woodcock, former director of the Center for Drug Evaluation and Research at FDA, and Paul T. Kim, principal of Kendall Square Policy Strategies LLC, were appointed to the board of directors at Friends of Cancer Research.
